This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.
Zydelig (idelalisib) has been indicated in final draft guidance for patients whose leukaemia has come back less than 24 months after previous treatment. ... had agreed to provide idelalisib to the NHS at a reduced price in the initial submission. “
Imbruvica is one of a number of new therapies for CLL reaching or near the market, with others including Gilead Sciences' Zydelig (idelalisib) and AbbVie/Roche's soon-to-be-filed
If approved, venetoclax will compete in the market with other new therapies for CLL, including Johnson &Johnson's first-in-class BTK inhibitor Imbruvica (ibrutinib) and Gilead Sciences' Zydelig (idelalisib), which
Specifically, England's drug pricing watchdog has opened a consultation on its preliminary draft guidance for the drug Zydelig (idelalisib) for patients with chronic lymphocytic leukaemia (CLL).
nitro-dihydro-imidazooxazole drug for multidrug-resistant tuberculosis (MDR-TB); Gilead Sciences' Zydelig (idelalisib) for certain types of leukaemia and lymphoma, which inhibits a protein that plays a role in the
Revlimid (lenalidomide). Myeloma. Eisai. Halaven (eribulin). Breast cancer. Gilead Sciences. Zydelig (idelalisib).
More from news
Approximately 2 fully matching, plus 17 partially matching documents found.